New drug aims to shrink polyps in inherited colon cancer condition
NCT ID NCT06557733
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether the drug TPST-1495 can reduce the number and size of polyps in the small bowel and colon of people with familial adenomatous polyposis (FAP), an inherited condition that greatly raises colon cancer risk. About 38 participants will take the drug by mouth and undergo endoscopies to measure polyp changes. The study is currently on hold.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TPST-1495 (a drug that blocks certain prostaglandin receptors to reduce polyp growth)
What this could lead to
If it works, this could offer a new way to reduce polyp burden in people with FAP, potentially lowering their cancer risk without needing more surgeries.
What could go wrong
This is a small, early-phase trial (38 people) that is currently suspended. The drug may not shrink polyps enough, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States